Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review
Cephalalgia · 2023
DOI: 10.1177/03331024221137091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cephalalgia, 2023. Verfasst von Bianca Raffaelli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Calcitonin gene-related peptide-targeted drugs have proven safe and effective for migraine prevention in large randomized-controlled, double-blind trials with an average duration of six months. Open-label studies may provide additional information on the long-term safety and efficacy of these substances.
Methods
We searched PubMed for open-label trials with calcitonin gene-related peptide(-receptor) monoclonal antibodies and calcitonin gene-related peptide-receptor antagonists. We summarized and critically analyzed the literature in a narrative way.
Results
Overall, 13 open-label trials were included in this review (n = 4 for erenumab, n = 4 for galcanezumab, n = 3 for fremanezumab, n = 1 for eptinezumab, n = 1 for atogepant). Open-label trial duration ranged between 12 and 264 weeks. No safety concerns emerged, and the adverse events profile was similar to the double-blind study phase. Discontinuation rates were generally low with >75% of patients remaining in the trials after one year. Efficacy data showed a sustained reduction of migraine frequency throughout the trials, along with a lasting improvement in quality of life.
Conclusions
The open-label study program for calcitonin gene-related peptide-targeted migraine preventives confirms the favorable safety and efficacy profile of these drugs over time. Treatment adherence appears higher than with previous unspecific migraine preventives. Real-world data and post-marketing surveillance studies may corroborate and complement open-label results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Clinician Scientist Program, Berlin Institute of Health, Berlin, Germany.
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
- MedStar Georgetown University Hospital, Washington, DC, USA.
ORCID-Profile: Bianca Raffaelli, Roberto De Icco
Zitieren
APA
Raffaelli, B., De Icco, R., Corrado, M., Terhart, M., & Ailani, J. (2023). Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review. Cephalalgia. https://doi.org/10.1177/03331024221137091
Vancouver
Raffaelli B, De Icco R, Corrado M, Terhart M, Ailani J. Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review. Cephalalgia. 2023. doi:10.1177/03331024221137091
BibTeX
@article{Raffaelli2023,
author = {Raffaelli, Bianca and De Icco, Roberto and Corrado, Michele and Terhart, Maria and Ailani, Jessica},
title = {Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review},
journal = {Cephalalgia},
year = {2023},
doi = {10.1177/03331024221137091}
}
EUVIMED